MAPK8 and ovarian cancer: Reports from the same research group found JNK inhibition by pharmacological drugs or genetic targeting could result in the loss of self-renewal and tumor-initiating capacity of CSC derived from ovarian cancer cell line A2780 [47] and stem-like glioblastoma cells [48].